Longeveron Logo.jpg
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET | Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Vaccinex logo
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024 08:30 ET | Vaccinex, Inc.
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex logo
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024 08:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024 07:00 ET | Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
tiziana-logo.png
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
February 22, 2024 06:05 ET | RetinalGeniX Technologies, Inc.
RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024 08:00 ET | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Op-Ed Submission: Al
Op-Ed Submission: Alberta’s Alarming Rise in Dementia
February 06, 2024 15:07 ET | Alzheimer Society of Alberta and NWT
Edmonton, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Op-Ed: Alberta’s Alarming Rise in Dementia By Dr. Roger Wong, Member of the Order of Canada, clinical professor in the Division of Geriatric Medicine in...